Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the third quarter ended March 31, 2023.
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the third quarter ended March 31, 2023.